Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
Shigeto M, Cha CY, Rorsman P, Kaku K
In addition to health risks, buyers may face fines or legal consequences
This article outlines the key principles for safe storage, refrigeration, and transport
Here is the step-by-step process when consulting an online GLP-1 medication doctor through Medical Wellness Doc: 1
All electrophysiology recordings were performed at ambient temperature
